Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
Michael Migden, MD,
Carmen Loquai, MD, PhD,
Caroline Robert, MD, PhD,
Jean-François Baurain, MD, PhD,
Nicholas Squittieri, MD,
Ramon Arntz, Dr,
Jörg Dierlamm, BSc,
Brigitte Dréno, MD, PhD
Affiliations
Michael Migden, MD
Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas; Correspondence to: Michael Migden, MD, 6655 Travis St, #700, Houston, TX 77030
Carmen Loquai, MD, PhD
Department of Dermatology, University Medical Center Mainz, Mainz, Germany
Caroline Robert, MD, PhD
Department of Dermatology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France
Jean-François Baurain, MD, PhD
Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Institute for Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium
Nicholas Squittieri, MD
Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey
Ramon Arntz, Dr
Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands
Jörg Dierlamm, BSc
Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands
Brigitte Dréno, MD, PhD
Department of Dermatology, University Hospital Nantes, Nantes, France
